AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from the CDSCO, ...

Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP inhibitor drug, olaparib, according to new research published in the journal ...

Olaparib monotherapy may be a treatment option for some patients with high-risk biochemically recurrent prostate cancer, according to researchers.

In a regulatory filing, the company said it has received permission from the Central Drugs Standard Control Organisation ...

The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the ...

This approval establishes the use of Olaparib in combination with Durvalumab as a maintenance treatment for adult patients ...

Olaparib in combination with Durvalumab is indicated for the maintenance treatment of adult patients with advanced or ...

Bangalore: AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from ...

AstraZeneca Pharma India has received approval from the CDSCO for Olaparib film-coated tablets, set to launch in India for ...

AstraZeneca Pharma India Ltd. has received approval from CDSCO to import and sell Lynparza (Olaparib) in India. Lynparza will ...